^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    goserelin acetate

    i
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    Apply
    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE) (NCT05607004)
    Phase 2
    Atossa Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/14/2023
    Primary completion :
    02/01/2026
    Completion :
    09/01/2026
    HER-2 • ER
    |
    HER-2 negative
    |
    exemestane • goserelin acetate
    [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (CAAA603B12101) (NCT05870579)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/13/2023
    Primary completion :
    12/30/2026
    Completion :
    01/26/2032
    HER-2 • ER
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603
    A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU) (NCT04325828)
    Phase 2
    Janssen Pharmaceutical K.K.
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/07/2020
    Primary completion :
    06/09/2021
    Completion :
    12/31/2027
    AR
    |
    AR positive
    |
    apalutamide • goserelin acetate
    Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/29/2014
    Primary completion :
    05/05/2020
    Completion :
    06/25/2025
    HER-2 • ER • PGR
    |
    exemestane • Jingzhuda (entinostat) • goserelin acetate
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (NCT06348134)
    Phase 2
    University of Chicago
    Not yet recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/01/2026
    Primary completion :
    07/01/2034
    Completion :
    07/01/2036
    HER-2
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) (NCT05879926)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/31/2023
    Primary completion :
    01/01/2032
    Completion :
    07/01/2034
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    triptorelin • goserelin acetate
    Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors (NCT04126070)
    Phase 2
    Xiao X. Wei, MD
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/11/2020
    Primary completion :
    10/24/2024
    Completion :
    06/30/2025
    PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N) (NCT05582499)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    11/01/2022
    Primary completion :
    12/31/2024
    Completion :
    09/01/2025
    HER-2 • PGR • CD8 • FOXC1
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Ariely (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune) (NCT05498272)
    Phase 2
    Rana McKay, MD
    Recruiting
    Last update posted :
    10/24/2024
    Initiation :
    02/01/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2
    |
    Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma (BTCRC-HN17-111) (NCT03942653)
    Phase 2
    Manish Patel
    Recruiting
    Last update posted :
    10/11/2024
    Initiation :
    05/30/2019
    Primary completion :
    09/01/2025
    Completion :
    10/01/2025
    AR
    |
    AR positive
    |
    Keytruda (pembrolizumab) • goserelin acetate
    FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (NCT03944434)
    Phase 2
    Fondazione Sandro Pitigliani
    Active, not recruiting
    Last update posted :
    09/25/2024
    Initiation :
    12/27/2018
    Primary completion :
    12/27/2024
    Completion :
    11/27/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (S1802) (NCT03678025)
    Phase 3
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    08/16/2024
    Initiation :
    09/24/2018
    Primary completion :
    04/01/2028
    Completion :
    10/01/2031
    SYP
    |
    docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)
    Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB) (NCT05163106)
    Phase 2
    University Hospital, Akershus
    Completed
    Last update posted :
    08/02/2024
    Initiation :
    12/01/2022
    Primary completion :
    07/30/2024
    Completion :
    07/30/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • goserelin acetate
    Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (NCT06528210)
    Phase 2
    OHSU Knight Cancer Institute
    Not yet recruiting
    Last update posted :
    07/30/2024
    Initiation :
    08/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) (NCT05694819)
    Phase 2
    National Cancer Center Hospital East
    Active, not recruiting
    Last update posted :
    06/21/2024
    Initiation :
    04/17/2020
    Primary completion :
    08/01/2024
    Completion :
    02/01/2026
    AR
    |
    AR positive
    |
    Nubeqa (darolutamide) • goserelin acetate
    Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (NCT04551495)
    Phase 2
    Jules Bordet Institute
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/01/2024
    Completion :
    10/01/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Rozlytrek (entrectinib) • letrozole • goserelin acetate
    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (NCT04931342)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    10/07/2021
    Primary completion :
    05/30/2028
    Completion :
    12/31/2028
    ER
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
    Contributions to Hypertension With Androgen Deprivation Therapy (ARCH) (NCT05700903)
    Phase 4
    University of Colorado, Denver
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    09/20/2023
    Primary completion :
    03/31/2028
    Completion :
    03/31/2028
    LCN2
    |
    Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension
    Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC (NCT05720260)
    Phase 2
    National Taiwan University Hospital
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    01/17/2023
    Primary completion :
    12/31/2024
    Completion :
    01/31/2027
    ER
    |
    ER positive
    |
    Imfinzi (durvalumab) • fulvestrant • Truqap (capivasertib) • goserelin acetate
    A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (GO39932) (NCT03332797)
    Phase 1
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    11/27/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (GDC-9545)
    Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer (NCT03860987)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    04/30/2019
    Primary completion :
    08/31/2025
    Completion :
    08/01/2028
    EGFR
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • goserelin acetate
    Detect V / CHEVENDO (Chemo vs. Endo) (DETECT V) (NCT02344472)
    Phase 3
    Prof. Wolfgang Janni
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    09/01/2015
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    HER-2
    |
    HER-2 positive • HR positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (NCT03671330)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/29/2018
    Primary completion :
    04/25/2022
    Completion :
    04/15/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    01/15/2014
    Primary completion :
    10/31/2016
    Completion :
    12/31/2024
    HER-2 • ER
    |
    TILs
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
    Phase II Dutasteride in Combination With CAB vs CAB in SDC (DUCT) (NCT05513365)
    Phase 2
    Radboud University Medical Center
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    09/27/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    AR
    |
    AR positive
    |
    bicalutamide • goserelin acetate
    Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (ADJUVANT WIDER) (NCT05827081)
    Phase 3
    Novartis Pharmaceuticals
    Suspended
    Last update posted :
    04/24/2024
    Initiation :
    02/28/2024
    Primary completion :
    09/07/2029
    Completion :
    09/20/2030
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (PH002-TP-II) (NCT03272477)
    Phase 2
    Palleos Healthcare GmbH
    Completed
    Last update posted :
    04/17/2024
    Initiation :
    10/05/2017
    Primary completion :
    07/14/2020
    Completion :
    03/04/2024
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab) • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • cyclophosphamide intravenous
    Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE) (NCT03822468)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    06/11/2019
    Primary completion :
    06/11/2021
    Completion :
    07/01/2024
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) (PALOMA3) (NCT01942135)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    04/04/2024
    Initiation :
    09/26/2013
    Primary completion :
    12/05/2014
    Completion :
    09/28/2022
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • goserelin acetate
    Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) (NCT03573648)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    11/13/2018
    Primary completion :
    07/31/2024
    Completion :
    12/31/2025
    ER
    |
    ER positive
    |
    Ibrance (palbociclib) • tamoxifen • Bavencio (avelumab) • Eligard (leuprolide acetate) • goserelin acetate
    Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve) (NCT03056755)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    08/14/2017
    Primary completion :
    06/14/2021
    Completion :
    07/17/2025
    HER-2 • ER • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    Piqray (alpelisib) • fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension
    PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (PATHWAY) (NCT03423199)
    Phase 3
    National Cancer Center, Japan
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    02/09/2018
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • tamoxifen • goserelin acetate
    Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (NCT03007979)
    Phase 2
    Washington University School of Medicine
    Completed
    Last update posted :
    03/20/2024
    Initiation :
    06/15/2017
    Primary completion :
    03/13/2020
    Completion :
    03/31/2023
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • goserelin acetate
    Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7) (NCT02278120)
    Phase 3
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    11/20/2014
    Primary completion :
    08/21/2017
    Completion :
    04/20/2023
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01) (NCT05949541)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    07/26/2023
    Primary completion :
    07/01/2026
    Completion :
    01/01/2028
    HER-2
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) (NCT05891093)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    06/01/2023
    Primary completion :
    05/31/2028
    Completion :
    05/31/2031
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • AiRuiYi (fluzoparib) • goserelin acetate
    Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (NCT04513717)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/15/2020
    Primary completion :
    12/31/2033
    Completion :
    12/31/2033
    CD4
    |
    abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)
    SNF Platform Study of HR+/ HER2-advanced Breast Cancer (BCTOP-L-M05) (NCT05594095)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    12/30/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive
    |
    sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)